Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR1D | P28221 | 3/20 | 0.39 |
| ▸ | HTR1B | P28222 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19179854 | 0.88 | HSD11B1 (0.56) | HSD11B1CXCR2CXCR1HTR1AHTR1D | |
| SCHEMBL27351302 | 0.84 | HSD11B1 (0.56) | HSD11B1CXCR2CXCR1HTR1AHTR1D | |
| SCHEMBL1748180 | 0.81 | HSD11B1 (0.56) | HSD11B1CXCR2CXCR1HTR1AHTR1D | |
| SCHEMBL3362412 | 0.80 | HSD11B1 (0.55) | HSD11B1CXCR2CXCR1HTR1AHTR1D | |
| SCHEMBL17480164 | 0.79 | ABL1 (0.46) | MAOBMAOA | |
| SCHEMBL29786514 | 0.79 | ABL1 (0.46) | MAOBMAOA | |
| SCHEMBL3491420 | 0.78 | HSD11B1 (0.50) | HSD11B1ALDH1A1 | |
| SCHEMBL27636766 | 0.78 | HSD11B1 (0.53) | HSD11B1CXCR2CXCR1HTR1AHTR1D | |
| SCHEMBL17355686 | 0.77 | HTR1D (0.43) | HSD11B1CXCR2CXCR1HTR1AHTR1D | |
| SCHEMBL5565709 | 0.77 | ALDH1A1 (0.51) | HSD11B1CXCR2CXCR1HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034687-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-06-15 | — | — | US | disclosed |
| CN-107406440-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20200308166-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2020-10-01 | — | — | US | disclosed |
| EP-3271355-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-10723729-B2 | BACE1 inhibitors | Hoffmann-Le Roche Inc. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190337936-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-11-07 | — | — | US | disclosed |
| US-10399969-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180319787-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2018-11-08 | — | — | US | disclosed |
| US-20180057485-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | US | disclosed |
| EP-3271355-A1 | BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016150785-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337936-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | HSD11B1 138/4885KAT6A 2630/4885CXCR2 4050/4885 |
| US-10399969-B2 | BACE1 inhibitors | BACE1, BACE2, APP | HSD11B1 138/4885KAT6A 2630/4885CXCR2 4050/4885 |
| US-20180319787-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | HSD11B1 138/4885KAT6A 2630/4885CXCR2 4050/4885 |
| US-20200308166-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | HSD11B1 138/4885KAT6A 2630/4885CXCR2 4050/4885 |
| US-10723729-B2 | BACE1 inhibitors | BACE1, BACE2, APP | HSD11B1 138/4885KAT6A 2630/4885CXCR2 4050/4885 |
| US-20180057485-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | HSD11B1 138/4885KAT6A 2630/4885CXCR2 4050/4885 |
| US-11034687-B2 | BACE1 inhibitors | BACE1, BACE2, APP | HSD11B1 138/4885KAT6A 2630/4885CXCR2 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.